Reported net loss of $1,781,757 CAD for Q3 ended September 30, 2025.
R&D expenses: $1,102,371 CAD; G&A expenses:
$539,174 CAD.
Cash and cash equivalents:
$822,293 CAD as of September 30, 2025.
Announcement made on December 1, 2025.
Highlighted pre-clinical data on AI-discovered ATR inhibitor (kt-5000 series) showing CNS penetration, presented October 27, 2025 at AACR-NCI-EORTC conference.
Working capital deficit of $489,279 CAD as of September 30, 2025.